Clinical Trial Update: Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating sintilimab, pegylated asparaginase (pegaspargase), and anlotinib for stage IV Natural Killer / T-cell lymphoma of the n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer T-cell Lymphoma Nasal Type

Drugs mentioned

• Anlotinib (anlotinib)
• Pegaspargase (pegaspargase)
• Sintilimab (sintilimab)

Snippet

Sponsor: Rong Tao | Conditions: Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Phase 2 | Status: UNKNOWN